585 related articles for article (PubMed ID: 34793971)
1. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
[TBL] [Abstract][Full Text] [Related]
2. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
[TBL] [Abstract][Full Text] [Related]
3. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
[TBL] [Abstract][Full Text] [Related]
4. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
5. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
[TBL] [Abstract][Full Text] [Related]
6. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry.
Peri-Okonny PA; Mi X; Khariton Y; Patel KK; Thomas L; Fonarow GC; Sharma PP; Duffy CI; Albert NM; Butler J; Hernandez AF; McCague K; Williams FB; DeVore AD; Patterson JH; Spertus JA
JACC Heart Fail; 2019 Apr; 7(4):350-358. PubMed ID: 30738978
[TBL] [Abstract][Full Text] [Related]
7. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
Vaduganathan M; Fonarow GC; Greene SJ; DeVore AD; Kavati A; Sikirica S; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
JACC Heart Fail; 2020 Jun; 8(6):469-480. PubMed ID: 32387066
[TBL] [Abstract][Full Text] [Related]
8. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry.
Greene SJ; Ezekowitz JA; Anstrom KJ; Demyanenko V; Givertz MM; Piña IL; O'Connor CM; Koglin J; Roessig L; Hernandez AF; Armstrong PW; Mentz RJ
J Card Fail; 2022 Jul; 28(7):1063-1077. PubMed ID: 35301107
[TBL] [Abstract][Full Text] [Related]
9. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS
Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001
[TBL] [Abstract][Full Text] [Related]
10. Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction.
Vaduganathan M; Fonarow GC; Greene SJ; Devore AD; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
J Card Fail; 2022 Feb; 28(2):191-201. PubMed ID: 34428591
[TBL] [Abstract][Full Text] [Related]
11. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD
Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure.
Yan CL; Gallo RA; Vasquez Martinez M; Rivera Rodriguez B; Trujillo L; Thakkar Rivera N; Hoffman JE
Am J Cardiol; 2023 Oct; 204():360-365. PubMed ID: 37573615
[TBL] [Abstract][Full Text] [Related]
13. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
14. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Fonarow GC; DeVore AD; Sharma PP; Vaduganathan M; Albert NM; Duffy CI; Hill CL; McCague K; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Butler J
J Am Coll Cardiol; 2019 May; 73(19):2365-2383. PubMed ID: 30844480
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice.
Smith KV; Dunning JR; Fischer CM; MacLean TE; Bosque-Hamilton JW; Fera LE; Grant JY; Zelle DJ; Matta L; Gaziano TA; MacRae CA; Scirica BM; Desai AS
J Pharm Pract; 2022 Oct; 35(5):747-751. PubMed ID: 33813934
[TBL] [Abstract][Full Text] [Related]
16. Adherence to Treatment Guidelines in Ambulatory Heart Failure Patients with Reduced Ejection Fraction in a Latin-American Country: Observational Study of the Colombian Heart Failure Registry (RECOLFACA).
Rivera-Toquica A; Echeverría LE; Arias-Barrera CA; Mendoza-Beltrán F; Hoyos-Ballesteros DH; Plata-Mosquera CA; Ortega-Madariaga JC; Carvajal-Estupiñán JF; Quintero-Yepes V; Zárate-Correa LC; García-Peña ÁA; Velásquez-López N; Anchique CV; Saldarriaga CI; Gómez-Mesa JE
Cardiology; 2024; 149(3):228-236. PubMed ID: 38359813
[TBL] [Abstract][Full Text] [Related]
17. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
[TBL] [Abstract][Full Text] [Related]
18. Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients.
Srivastava PK; DeVore AD; Hellkamp AS; Thomas L; Albert NM; Butler J; Patterson JH; Spertus JA; Williams FB; Duffy CI; Hernandez AF; Fonarow GC
JACC Heart Fail; 2021 Jan; 9(1):28-38. PubMed ID: 33309579
[TBL] [Abstract][Full Text] [Related]
19. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ
Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917
[TBL] [Abstract][Full Text] [Related]
20. Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial.
Cox ZL; Zalawadiya SK; Simonato M; Redfors B; Zhou Z; Kotinkaduwa L; Zile MR; Udelson JE; Lim DS; Grayburn PA; Mack MJ; Abraham WT; Stone GW; Lindenfeld J
JACC Heart Fail; 2023 Jul; 11(7):791-805. PubMed ID: 37115135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
